The 90-Minute Window That Defines Survival
A 58-year-old man arrives in the emergency department at 2 AM with crushing substernal chest pain radiating to his left arm. He is diaphoretic, nauseated, and visibly distressed. His troponin is pending. The ECG is in your hands. What happens in the next 90 minutes will determine whether this man walks out of the hospital or never leaves the ICU.
This is the clinical reality of acute coronary syndrome (ACS) — a spectrum of conditions caused by acute myocardial ischemia that ranges from unstable angina to ST-elevation myocardial infarction (STEMI). The critical first decision is distinguishing STEMI from NSTEMI, because the management pathways diverge immediately and dramatically. STEMI demands emergent reperfusion within 90 minutes. NSTEMI requires risk stratification that determines whether catheterization happens in 2 hours, 24 hours, or can be deferred entirely.
This article provides a systematic, evidence-based decision algorithm for ACS management based on the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes and the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Every clinician who manages chest pain — emergency physicians, cardiologists, internists, and critical care nurses — needs this algorithm committed to memory.
Step 1: The 12-Lead ECG — Your First and Most Important Decision Point
The 12-lead ECG must be obtained and interpreted within 10 minutes of first medical contact. This is not a suggestion — it is a Class I recommendation in both AHA and ESC guidelines. The ECG is the single test that bifurcates the entire ACS management pathway.
STEMI criteria: New ST-elevation at the J-point in ≥2 contiguous leads: ≥1 mm in all leads except V2-V3, where the threshold is ≥2 mm in men ≥40 years, ≥2.5 mm in men <40 years, and ≥1.5 mm in women. A new or presumably new left bundle branch block (LBBB) with clinical suspicion of ischemia should be treated as a STEMI equivalent. Posterior MI (ST depression in V1-V3 with ST elevation in V7-V9) and de Winter T-waves (upsloping ST depression with tall, symmetric T-waves in precordial leads) are also STEMI equivalents that require emergent reperfusion.
NSTEMI/UA criteria: ST depression ≥0.5 mm, T-wave inversions ≥1 mm, or a normal/non-diagnostic ECG in the setting of elevated troponin (NSTEMI) or ischemic symptoms without troponin elevation (unstable angina). Importantly, a normal ECG does not exclude ACS — up to 6% of patients with a normal initial ECG will have NSTEMI.
If the initial ECG is non-diagnostic but clinical suspicion remains high, serial ECGs every 15-30 minutes are recommended. Right-sided leads (V4R) should be obtained when inferior STEMI is identified to evaluate for right ventricular involvement, which changes fluid management strategy.
The STEMI Pathway: Time Is Myocardium
When the ECG shows STEMI criteria, the clock starts. Every minute of delay in reperfusion translates to additional myocardial necrosis, and the relationship between time-to-reperfusion and mortality is well established. The 2025 ACC/AHA guidelines emphasize total ischemic time — the interval from symptom onset to reperfusion — as the critical metric, with a target of under 120 minutes.
Primary PCI: The Gold Standard
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy when it can be performed within 90 minutes of first medical contact (door-to-balloon time) at a PCI-capable facility, or within 120 minutes if transfer to a PCI-capable facility is required. This is a Class I, Level of Evidence A recommendation.
The target is not just door-to-balloon — it is first medical contact to device. This means the clock starts when EMS arrives on scene or when the patient walks through the ED door, whichever comes first. Systems of care that activate the catheterization lab from the field based on prehospital ECG interpretation consistently achieve shorter reperfusion times.
During PCI, the interventional cardiologist performs coronary angiography to identify the culprit lesion, then restores flow with balloon angioplasty and stent placement (drug-eluting stents are standard). The 2025 guidelines recommend culprit-lesion-only PCI during the index procedure for most patients, with staged revascularization of non-culprit lesions during the index hospitalization or within 45 days for patients with multivessel disease (based on the COMPLETE trial).
Fibrinolytic Therapy: When PCI Is Not Available
If primary PCI cannot be achieved within 120 minutes of first medical contact, fibrinolytic therapy should be administered within 30 minutes of hospital arrival (door-to-needle time). The preferred agents are tenecteplase (weight-based single IV bolus) or alteplase (accelerated infusion over 90 minutes).
After fibrinolysis, patients should be transferred to a PCI-capable facility for routine angiography within 2-24 hours (pharmacoinvasive strategy), regardless of whether fibrinolysis appears successful. If there are signs of failed reperfusion (persistent ST elevation, ongoing chest pain, hemodynamic instability) at 60-90 minutes post-fibrinolysis, rescue PCI should be performed emergently.
Absolute contraindications to fibrinolysis include: active internal bleeding (excluding menses), history of hemorrhagic stroke, ischemic stroke within 3 months, intracranial neoplasm, suspected aortic dissection, and significant head/facial trauma within 3 months.
Adjunctive Pharmacotherapy for STEMI
Alongside reperfusion, STEMI patients receive a standardized pharmacotherapy regimen:
Antiplatelet therapy: Aspirin 162-325 mg loading dose (chewed, not swallowed) plus a P2Y12 inhibitor. For primary PCI, prasugrel 60 mg or ticagrelor 180 mg loading dose is preferred over clopidogrel (based on TRITON-TIMI 38 and PLATO trials). Prasugrel is contraindicated in patients with prior stroke/TIA, age ≥75, or weight <60 kg.
Anticoagulation: Unfractionated heparin (UFH) is standard during PCI. Bivalirudin is an alternative, particularly in patients at high bleeding risk. Enoxaparin may be used if PCI is delayed.
Additional therapies: Beta-blockers (oral, within 24 hours if no contraindications), high-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg), ACE inhibitor or ARB (within 24 hours for anterior MI, heart failure, or EF ≤40%), and aldosterone antagonist (for EF ≤40% with heart failure or diabetes).
The NSTEMI Pathway: Risk-Stratified Timing
Unlike STEMI, where the management is binary (reperfuse now), NSTEMI management is risk-stratified. The timing of invasive angiography depends on the patient's risk profile, and getting this timing right is the central challenge of NSTEMI management.
Confirming the Diagnosis: High-Sensitivity Troponin
The diagnosis of NSTEMI requires evidence of myocardial injury — a rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit — in the clinical context of acute ischemia. High-sensitivity cardiac troponin (hs-cTn) assays have transformed NSTEMI diagnosis by enabling earlier detection and faster rule-out.
The ESC 0/1-hour algorithm uses two hs-cTn measurements at presentation and 1 hour later. Patients are triaged into three groups: rule-out (very low baseline value with minimal change), rule-in (high baseline value or significant rise at 1 hour), and observe (intermediate values requiring further testing at 3 hours). This algorithm has a negative predictive value >99% for rule-out and a positive predictive value >70% for rule-in.
The 2025 ACC/AHA guidelines endorse the 0/3-hour algorithm using conventional or high-sensitivity troponin, with serial measurements at 0 and 3-6 hours. A rising or falling pattern with at least one value above the 99th percentile, combined with ischemic symptoms or ECG changes, confirms NSTEMI.
Risk Stratification: GRACE, TIMI, and Clinical Judgment
Once NSTEMI is confirmed, risk stratification determines the urgency of invasive management. The two validated scoring systems are:
GRACE Risk Score (Global Registry of Acute Coronary Events): Incorporates age, heart rate, systolic blood pressure, creatinine, cardiac arrest at admission, ST-segment deviation, elevated cardiac biomarkers, and Killip class. A GRACE score >140 identifies high-risk patients who benefit from early invasive strategy. The GRACE score is the preferred risk stratification tool in ESC guidelines.
TIMI Risk Score (Thrombolysis in Myocardial Infarction): Uses 7 variables — age ≥65, ≥3 CAD risk factors, known CAD (≥50% stenosis), aspirin use in past 7 days, ≥2 anginal episodes in 24 hours, ST deviation ≥0.5 mm, and elevated cardiac markers. Score ranges from 0-7, with higher scores predicting greater 14-day risk of death, MI, or urgent revascularization.
Timing of Invasive Strategy
The 2025 ACC/AHA guidelines define four timing categories for coronary angiography in NSTEMI:
Immediate (within 2 hours): Patients with hemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical therapy, life-threatening arrhythmias (sustained VT, VF), mechanical complications of MI (acute mitral regurgitation, VSD), or acute heart failure clearly related to ACS. These patients are managed essentially like STEMI — emergent catheterization is required.
Early (within 24 hours): Patients with a GRACE score >140, dynamic ST or T-wave changes (particularly intermittent ST elevation), or a rise or fall in troponin consistent with MI. The TIMACS trial demonstrated that an early invasive strategy (within 24 hours) reduced the composite of death, MI, and stroke compared to a delayed strategy in high-risk patients.
Delayed invasive (within 72 hours): Patients with intermediate risk features — diabetes mellitus, renal insufficiency (eGFR <60), reduced LVEF (<40%), early post-infarction angina, prior PCI or CABG, or GRACE score 109-140. These patients benefit from invasive evaluation but do not require the urgency of the early group.
Selective invasive (ischemia-guided): Low-risk patients (GRACE <109, TIMI 0-2) without recurrent symptoms may be managed with an ischemia-guided strategy — non-invasive stress testing followed by angiography only if inducible ischemia is demonstrated. This approach avoids unnecessary catheterization in patients who are unlikely to benefit from revascularization.
Dual Antiplatelet Therapy: Duration and De-Escalation
After PCI for ACS (both STEMI and NSTEMI), dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is the standard of care. The critical questions are: which P2Y12 inhibitor, for how long, and when to de-escalate?
Standard duration: 12 months of DAPT is the default recommendation for ACS patients treated with PCI. Ticagrelor 90 mg twice daily or prasugrel 10 mg daily are preferred over clopidogrel based on superior outcomes in the PLATO and TRITON-TIMI 38 trials.
Shortened DAPT (1-3 months): For patients at high bleeding risk (defined by the ARC-HBR criteria — including age >75, oral anticoagulation use, moderate-to-severe CKD, anemia, low platelet count, or prior bleeding), DAPT can be shortened to 1-3 months followed by P2Y12 inhibitor monotherapy. The TWILIGHT, TICO, and STOPDAPT-2 ACS trials support this approach.
Extended DAPT (>12 months): For patients at high ischemic risk and low bleeding risk, extended DAPT up to 36 months may be considered. The PEGASUS-TIMI 54 trial showed that ticagrelor 60 mg twice daily plus aspirin reduced cardiovascular events in stable patients 1-3 years post-MI.
De-escalation strategies: Transitioning from prasugrel or ticagrelor to clopidogrel after the acute phase (typically 1-3 months) is an emerging strategy supported by the TOPIC and HOST-REDUCE-POLYTECH-ACS trials. This approach balances ischemic protection during the high-risk early period with reduced bleeding risk during the maintenance phase. Guided de-escalation using platelet function testing is an option but not yet a strong recommendation.
STEMI vs NSTEMI: Side-by-Side Comparison
Understanding the key differences between STEMI and NSTEMI at a glance is essential for rapid clinical decision-making. The following comparison highlights the critical distinctions in pathophysiology, diagnosis, and management:
Pathophysiology: STEMI involves complete thrombotic occlusion of a coronary artery, causing transmural ischemia. NSTEMI involves partial or intermittent occlusion, causing subendocardial ischemia. This fundamental difference explains why STEMI produces ST elevation (transmural injury current) while NSTEMI produces ST depression or T-wave inversion (subendocardial injury).
ECG findings: STEMI shows ST elevation in ≥2 contiguous leads meeting voltage criteria. NSTEMI shows ST depression, T-wave inversions, or may be normal/non-diagnostic.
Troponin: Both STEMI and NSTEMI have elevated troponin. Unstable angina has normal troponin but ischemic symptoms. The magnitude of troponin elevation does not reliably distinguish STEMI from NSTEMI — the ECG does.
Reperfusion urgency: STEMI requires emergent reperfusion (PCI within 90 minutes or fibrinolysis within 30 minutes). NSTEMI timing is risk-stratified (2 hours to 72 hours or selective).
Mortality: In-hospital mortality for STEMI is approximately 5-8%. NSTEMI in-hospital mortality is 3-5%, but long-term mortality at 6 months and beyond is similar or even higher for NSTEMI, reflecting the higher burden of comorbidities and multivessel disease in this population.
Clinical Pitfalls: Where the Algorithm Breaks Down
Even the best algorithm fails if the clinician doesn't recognize its limitations. Here are the most dangerous pitfalls in ACS management:
The "normal" ECG trap: A normal ECG does not exclude ACS. Circumflex artery occlusion, posterior MI, and early presentations may have non-diagnostic initial ECGs. Always obtain serial ECGs and posterior leads (V7-V9) when clinical suspicion is high.
STEMI equivalents: Left main occlusion (diffuse ST depression with ST elevation in aVR), de Winter T-waves, Wellens syndrome (deeply inverted T-waves in V2-V3 suggesting critical LAD stenosis), and new LBBB are all patterns that require emergent catheterization but may be missed if the clinician is only looking for classic ST elevation.
Type 2 MI vs Type 1 MI: Not every troponin elevation is ACS. Type 2 MI occurs when myocardial oxygen supply-demand mismatch (from tachycardia, hypotension, anemia, respiratory failure) causes troponin elevation without plaque rupture. The treatment is correcting the underlying cause, not catheterization. Distinguishing Type 1 from Type 2 MI requires clinical context — the troponin alone cannot tell you.
Right ventricular MI: When inferior STEMI is accompanied by RV involvement (ST elevation in V4R), the management changes significantly. These patients are preload-dependent — nitroglycerin and diuretics can cause catastrophic hypotension. Volume resuscitation is the initial treatment, which is the opposite of standard left-sided MI management.
Cocaine-associated ACS: Beta-blockers are relatively contraindicated in cocaine-associated chest pain due to the risk of unopposed alpha-stimulation and coronary vasospasm. Benzodiazepines, nitroglycerin, and calcium channel blockers are first-line. This is a classic board question and a real clinical danger.
Post-MI Care: The GDMT Checklist
Surviving the acute event is only the beginning. Long-term outcomes after MI depend on guideline-directed medical therapy (GDMT) optimization before discharge and during follow-up. The post-MI medication checklist includes:
DAPT: Aspirin indefinitely plus P2Y12 inhibitor for 12 months (adjusted for bleeding risk as discussed above).
High-intensity statin: Atorvastatin 80 mg or rosuvastatin 20-40 mg for all ACS patients regardless of baseline LDL. Target LDL <55 mg/dL (ESC) or <70 mg/dL (AHA/ACC). Add ezetimibe or PCSK9 inhibitor if target not achieved.
Beta-blocker: For patients with reduced EF (≤40%). The evidence for beta-blockers in preserved-EF post-MI patients is being re-evaluated — the ABYSS and REDUCE-AMI trials suggest the benefit may be smaller than previously thought.
ACE inhibitor or ARB: For patients with anterior MI, heart failure, EF ≤40%, hypertension, diabetes, or CKD. ARNI (sacubitril/valsartan) may be considered instead of ACEi for patients with HFrEF.
Aldosterone antagonist: Eplerenone or spironolactone for patients with EF ≤40% and either heart failure symptoms or diabetes (based on the EPHESUS trial).
Cardiac rehabilitation: Class I recommendation for all post-MI patients. Cardiac rehab reduces cardiovascular mortality by 20-25% and is one of the most underutilized interventions in cardiology.
Master ACS Management with Interactive Tools
The ACS decision algorithm is complex — multiple branch points, time-sensitive decisions, and patient-specific variables that change the optimal approach. Reading about it is necessary but insufficient. Practicing the algorithm in realistic clinical scenarios is what builds the pattern recognition and decision speed that saves lives.
The Cardiovascular Bundle ($29) includes 38 interactive tools covering the full spectrum of cardiovascular medicine. For ACS management specifically, the ACS Clinical Decision Tool walks through the complete STEMI vs NSTEMI algorithm with interactive decision support, including ECG pattern recognition, risk score calculators (GRACE, TIMI, ARC-HBR), reperfusion timing guidance, and DAPT duration recommendations aligned with the 2025 ACC/AHA guidelines.
The ECG Interpretation Guide provides systematic ECG analysis with pattern libraries for STEMI, STEMI equivalents, and NSTEMI changes. The Chest Pain Differential Diagnosis Tool helps distinguish ACS from other causes of chest pain — aortic dissection, pulmonary embolism, pericarditis, and esophageal emergencies — each of which requires a fundamentally different treatment approach.
Combined with the Heart Failure Management Guide (for post-MI heart failure optimization), CV Procedures & Complications volumes (for understanding PCI, CABG, and their complications), and Chest Pain Clinical Cases (for interactive case-based practice), the Cardiovascular Bundle provides a complete toolkit for mastering the most time-critical decisions in medicine.